IPO registrations (S-1, F-1) · Registrants
Kalaris Therapeutics, Inc.
- SEC CIK
- 1754068 · filings on EDGAR ↗
- Name on the registration
- Allovir, Inc.
- Former names
- Allovir, Inc. (2019–2025); ViraCyte, Inc. (2018–2018)
- Registration
- Form S-1, first filed 2020-07-06, last 2020-07-23; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2020-07-30; declared effective 2020-07-29
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 400 CONNELL DRIVE, SUITE 5500, Berkeley Heights, NJ 07922
- EIN
- 83-1971007
- Ticker
- KLRS (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Kalaris Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2020-07-23)
- Final price
- $17.00 per share, within the range (424B4 filed 2020-07-30, an initial public offering)
- Shares sold
- 16,250,000
- Gross proceeds
- $276,250,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ALVR
- Lead underwriters
- Morgan Stanley; J.P. Morgan; Leerink Partners
- Syndicate
- Piper Sandler
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: KALARIS THERAPEUTICS INC EXACT (EIN (EXACT))
- Form D issuer: Allovir, Inc. EXACT (CIK (EXACT))
- SEC filer: Allovir, Inc. EXACT (CIK (EXACT))
- Person page: Jeffrey S Bornstein Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-07-06 | S-1 | S-1 (registration) | Allovir, Inc. | 0001193125-20-187665 ↗ |
| 2020-07-23 | S-1/A | S-1/A (amendment) | Allovir, Inc. | 0001193125-20-197425 ↗ |
| 2020-07-29 | EFFECT | EFFECT (declared effective) | Allovir, Inc. | 9999999995-20-001953 ↗ |
| 2020-07-30 | S-1MEF | S-1MEF (added securities) | Allovir, Inc. | 0001193125-20-203314 ↗ |
| 2020-07-30 | 424B4 | 424B4 (final prospectus) | Allovir, Inc. | 0001193125-20-204368 ↗ |
| 2022-02-28 | EFFECT | EFFECT (declared effective) | Allovir, Inc. | 9999999995-22-000522 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-07-23 | S-1/A | registration statement | $16.00–$18.00 | 14,750,000 | - | Nasdaq ALVR | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2020-07-30 | 424B4 | final prospectus | $17.00 | 16,250,000 | $276,250,000 | Nasdaq ALVR | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Atillasoy Ercem | Officer | See Remarks | 13 | 2020–2022 | |
| Bornstein Jeffrey S | Director | 10 | 2020–2024 | person page Fuzzy | |
| Brainard Diana | Director; Director,Officer | Chief Executive Officer | 39 | 2020–2024 | |
| Brenner Malcolm | Director | 12 | 2020–2024 | ||
| ElevateBio, LLC | Director,TenPercentOwner; TenPercentOwner | 3 | 2020–2022 | ||
| GADICKE ANSBERT | Director,TenPercentOwner | 6 | 2020–2022 | ||
| Green Jeremy | TenPercentOwner | 2 | 2020 | ||
| Hagen Brett R | Officer | Chief Accounting Officer | 48 | 2020–2026 | |
| Hallal David | Director; Director,Officer,TenPercentOwner; Director,TenPercentOwner | Chief Executive Officer | 18 | 2020–2026 | |
| Jovan-Embiricos Morana | Director; Director,TenPercentOwner | 14 | 2020–2026 | ||
| Leen Ann M. | Officer | Chief Scientific Officer | 13 | 2020–2023 | |
| Melian Agustin | Officer | Chief Medical Officer | 8 | 2020–2021 | |
| Miller Edward | Officer | General Counsel | 34 | 2020–2025 | |
| Redmile Group, LLC | TenPercentOwner | 2 | 2020 | ||
| Sinha Vikas | Director,Officer; Director,Officer,TenPercentOwner | See Remarks | 41 | 2020–2025 | |
| VAN BEEK JEROEN B | Officer | Chief Commercial Officer | 28 | 2020–2022 | |
| Vera Juan | Director | 11 | 2020–2024 | ||
| Wilson John Robert | Director | 6 | 2020–2021 | ||
| Tomasello Shawn | Director | 5 | 2022–2024 | ||
| F2 Bioscience AV 2022 LLC | Director,TenPercentOwner | 1 | 2022 | ||
| F2 Capital I 2020 | Director,TenPercentOwner | 1 | 2022 | ||
| F2 MC, LLC | Director,TenPercentOwner | 1 | 2022 | ||
| F2 MG Ltd | Director,TenPercentOwner | 1 | 2022 | ||
| F2 - TPO Investments LLC | Director,TenPercentOwner | 1 | 2022 | ||
| GILEAD SCIENCES, INC. | TenPercentOwner | 2 | 2022–2023 | ||
| Globeways Holdings II Ltd | Director,TenPercentOwner | 1 | 2022 | ||
| Globeways Holdings Ltd | Director,TenPercentOwner | 1 | 2022 | ||
| Adams Derek N. | Director | 4 | 2023–2024 | ||
| Piccina Cintia | Officer | Chief Commercial Officer | 2 | 2023 | |
| ADAMIS ANTHONY P | Director | 4 | 2025–2026 | ||
| AKKARAJU SRINIVAS | Director; Director,TenPercentOwner | 8 | 2025–2026 | ||
| Dybbs Michael | Director | 3 | 2025–2026 | ||
| Feinsod Matthew | Officer | Chief Medical Officer | 4 | 2025–2026 | |
| Ferrara Napoleone | Director | 4 | 2025–2026 | ||
| Oxtoby Andrew | Director,Officer | See Remarks | 4 | 2025–2026 | |
| PATEL SAMIR CHANDRAKANT | Director | 3 | 2025 | ||
| Samsara BioCapital GP, LLC | TenPercentOwner | 3 | 2025–2026 | ||
| Samsara BioCapital, L.P. | TenPercentOwner | 3 | 2025–2026 | ||
| PATTERSON LEONE D | Director | 3 | 2025–2026 | ||
| Gall Matthew | Officer | Chief Financial Officer | 3 | 2025–2026 | |
| Samsara Opportunity Fund GP, LLC | TenPercentOwner | 3 | 2025–2026 | ||
| Samsara Opportunity Fund, L.P. | TenPercentOwner | 3 | 2025–2026 | ||
| Bayko Liisa Ann | Officer | Chief Financial Officer | 2 | 2026 | |
| Vandekop Amy O'Leary | Officer | See Remarks; VP, Corporate Controller | 2 | 2026 | |
| KEATING LAURIE | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-05-22 | Allovir, Inc. | Biotechnology | $121,253,231 | $121,253,231 | 47 | 1 |
| 2018-10-02 | ViraCyte, Inc. | Biotechnology | $50,000,000 | $30,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Allovir, Inc. | TX | Form D private offerings | CIK (EXACT) |
| SEC filer | Kalaris Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | KALARIS THERAPEUTICS INC | EIN (EXACT) | ||
| Person page | Jeffrey S Bornstein | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NJ first:
- IGX CORP/DE NJ
- ADMA BIOLOGICS, INC. NJ
- Point of Care Nano-Technology, Inc. NJ
- Outlook Therapeutics, Inc. NJ
- Oyster Point Pharma, Inc. NJ
- Tevogen Inc. NJ
- TAMIR BIOTECHNOLOGY, INC. NJ
- GENTA INC DE/ NJ
- BioNTech SE 2M
- Immatics N.V. 2M
In other datasets, the same topic (Health) in NJ:
- Nonprofit: 1ST CEREBRAL PALSY OF NEW JERSEY INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health